GRANULES:NSE-Granules India Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 331.10

Change

-26.50 (-7.41)%

Market Cap

INR 88.80B

Volume

0.01B

Avg Analyst Target

INR 412.50 (+24.58%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Granules India Limited (GRANULES) Stock Analysis:
Based on the Granules India Limited stock forecasts from 4 analysts, the average analyst target price for Granules India Limited is INR 412.50 over the next 12 months. Granules India Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Granules India Limited is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Granules India Limited’s stock price was INR 331.10. Granules India Limited’s stock price has changed by +4.35% over the past week, +7.70% over the past month and -4.14% over the last year.

About

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, and internationally. The company's APIs in various therapeutic categories i ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-6.55 (-0.76%)

INR2,062.82B 34.19 18.42
DIVISLAB:NSE Divi's Laboratories Limited

+13.75 (+0.30%)

INR1,225.56B 57.37 37.09
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-16.80 (-0.36%)

INR777.90B 40.09 18.15
PEL:NSE Piramal Enterprises Limited

+28.90 (+1.09%)

INR630.78B 54.19 14.72
CADILAHC:NSE Cadila Healthcare Limited

-4.05 (-0.92%)

INR452.65B 9.44 14.02
ALKEM:NSE Alkem Laboratories Limited

-47.60 (-1.31%)

INR433.44B 25.45 17.60
LUPIN:NSE Lupin Limited

-9.25 (-0.97%)

INR432.30B 25.10 31.14
AUROPHARMA:NSE Aurobindo Pharma Limited

-9.35 (-1.35%)

INR407.32B 7.82 5.05
LAURUSLABS:NSE Laurus Labs Limited

-13.15 (-2.52%)

INR279.99B 27.73 18.17
IPCALAB:NSE IPCA Laboratories Limited

+0.75 (+0.07%)

INR269.52B 27.40 17.45

ETFs Containing GRANULES

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.52% 39% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.52% 39% F 14% F
Trailing 12 Months  
Capital Gain -4.14% 28% F 10% F
Dividend Return 0.36% 28% F 16% F
Total Return -3.78% 28% F 10% F
Trailing 5 Years  
Capital Gain 190.82% 76% C 78% C+
Dividend Return 4.39% 80% B- 50% F
Total Return 195.21% 78% C+ 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 44.97% 75% C 84% B
Dividend Return 0.73% 79% C+ 53% F
Total Return 45.70% 77% C+ 84% B
Risk Return Profile  
Volatility (Standard Deviation) 83.61% 31% F 26% F
Risk Adjusted Return 54.66% 69% D+ 80% B-
Market Capitalization 88.80B 74% C 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.71 63% D 56% F
Price/Book Ratio 3.62 48% F 32% F
Price / Cash Flow Ratio 20.53 46% F 31% F
EV/EBITDA 11.57 69% D+ 53% F
Management Effectiveness  
Return on Equity 22.26% 71% C- 81% B-
Return on Invested Capital 20.16% 74% C 89% B+
Return on Assets 10.14% 75% C 83% B
Debt to Equity Ratio 15.70% 28% F 46% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.47 77% C+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.